Artículos por temáticas

The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Munoz-Sanjuan I, Bates GP.

J Clin Invest. 2011 Feb;121(2):476-83. doi: 10.1172/JCI45364. Review.

The structural involvement of the cingulate cortex in premanifest and early Huntington's disease.

Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A, Sturrock A, Craufurd D, Stout JC, Leavitt BR, Barnes J, Tabrizi SJ, Scahill RI.

Mov Disord. 2011 Aug 1;26(9):1684-90. doi: 10.1002/mds.23747.

[Dropped head syndrome associated to craniofacial dystonia].

Garcia-Martin G, Padilla-Parrado F, Chamorro-Munoz MI, Gomez-Heredia MJ, Perez-Errazquin F, Romero-Acebal M.

Rev Neurol. 2011 May 16;52(10):637-9. Spanish. No abstract available.

Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntington's disease.

Müller HP, Süssmuth SD, Landwehrmeyer GB, Ludolph A, Tabrizi SJ, Kloppel S, Kassubek J.

Version 2. PLoS Curr. 2011 Dec 12 [revised 2012 Jan 1];3:RRN1292.

Biomarkers to Enable the Development of Neuroprotective Therapies for Huntington’s Disease.

Hersch SM, Rosas HD.

In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 11.

Gait and posture assessments of a patient treated with deep brain stimulation in dystonia using three-dimensional motion analysis systems.

Nakao S, Komatsu K, Sakai W, Kashihara M, Masuda Y, Nishikawa K, Okahisa T, Kondo S, Osawa T, Kaji R, Gotoh S, Nagahiro S, Takata S, Yasui N.

J Med Invest. 2011 Aug;58(3-4):264-72.

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.

Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, Bocharov EV, Bocharova OA, Polyschuk VV, Sherstnev VV, Morozova-Roche LA.

J Neuroimmunol. 2011 Apr;233(1-2):221-7. doi: 10.1016/j.jneuroim.2010.12.001. Erratum in: J Neuroimmunol. 2014 Mar 15;268(1-2):99. Bocharova, Olga R [corrected to Bocharova, Olga A].

A neurocomputational model of dopamine and prefrontal-striatal interactions during multicue category learning by Parkinson patients.

Moustafa AA, Gluck MA.

J Cogn Neurosci. 2011 Jan;23(1):151-67. doi: 10.1162/jocn.2010.21420.

Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

International Parkinson Disease Genomics Consortium., Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez

Lancet. 2011 Feb 19;377(9766):641-9. doi: 10.1016/S0140-6736(10)62345-8.

The PARLance of Parkinson disease.

McQuibban GA, Bulman DE.

Autophagy. 2011 Jul;7(7):790-2.

Evaluation and management of the non-motor features of Parkinson's disease.

Wishart S, Macphee GJ.

Ther Adv Chronic Dis. 2011 Mar;2(2):69-85. doi: 10.1177/2040622310387847.

Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles.

Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kim JW.

J Clin Neurol. 2011 Mar;7(1):19-24. doi: 10.3988/jcn.2011.7.1.19.

The influence of Nordic Walking training on sit-to-stand transfer in Parkinson patients.

Fritz B, Rombach S, Godau J, Berg D, Horstmann T, Grau S.

Gait Posture. 2011 Jun;34(2):234-8. doi: 10.1016/j.gaitpost.2011.05.004.

Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases.

Kawamata J, Shimohama S.

J Alzheimers Dis. 2011;24 Suppl 2:95-109. doi: 10.3233/JAD-2011-110173. Review.

Aetiopathogenesis of Parkinson's disease.

Schapira AH.

J Neurol. 2011 May;258(Suppl 2):S307-10. doi: 10.1007/s00415-011-6016-y. Review.